Anti-gpc1 monoclonal antibody, therapeutic and diagnostic uses thereof
OwnerGiuseppe TOFFOLI, Michele DAL BO +4inventors
InventorsGiuseppe TOFFOLI, Michele DAL BO, Paolo MACOR, Davide BUSATO, Sara CAPOLLA, Federica DI CINTIO
Life of this patent
Estimating the term…
Abstract
A monoclonal antibody of IgM isotype which specifically binds to the antigen glypican-1 (GPC1) in vitro, ex vivo and in vivo, is able to induce complement dependent cytotoxicity and reduce GPC1-expressing tumor masses in vivo. A nucleic acid construct and a transformed host cell are suitable for use in a method of recombinantly producing the anti-GPC1 monoclonal antibody and in diagnostic and therapeutic methods.
Claims22
A monoclonal antibody binding to the antigen glypican-1 (GPC1), wherein the monoclonal antibody is of IgM isotype and comprises three heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and three light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- HCDR1 includes the amino acid sequence of SEQ ID NO:
- 3,
- HCDR2 includes the amino acid sequence of SEQ ID NO:
- 5,
- HCDR3 includes the amino acid sequence of SEQ ID NO:
- 7,
- LCDR1 includes the amino acid sequence of SEQ ID NO:
- 9,
- LCDR2 includes the amino acid sequence of KVS, and
- LCDR3 includes the amino acid sequence of SEQ ID NO:
- 12.
(canceled)
(canceled)
Dependencies are inferred from the claim text.